Rarezot schreef op 10 maart 2020 09:25:
[...]
FL,
Thank you very much for your input. Of course the other companies don't do exactly the same as BCART, otherwise BCART would be obsolete... The other companies are more treatment focused, but I mainly chose them because they are Biotech companies in immuno-oncologie about as old as BCART and still on their path to profitability.
What I look for during steep declines is if I think the company might go bankrupt, and I believe BCART is safe for the coming 2-3years without a capital raise if they stay at the same sales numbers as last year (costs will keep decreasing).
I believe that if you are willing to sit out this bear market, and you were able to buy at about 50% (or less) of the valuation you make with bull market numbers, you will most likely make a good profit in the next bull market (and yes people, there will be a next bull market. The world is not ending and if it did, your money would be worthless anyway).
I agree with you that BCART has a lot of intangible assets and it is hard to put a price on that... But I think the current P/B value at 2.37 (P=4, without intangible assets P/B should be really close to 1) is too low especially if you compare that to the other companies, BioNTech is only starting its first-in-human clinical trials this year.
And of course the BCART share price probably will drop even further with corona... That's why I don't say people should rush out and buy shares right now, I only tell them what I think the share should be worth and they use that information however they like.
I have no idea about the E health record management, I'm sorry...
Rarezot